Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 2/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764934 | 0.87 | DRD2 (0.43) | DRD2NAMPTEPHX2RORCACACB | |
| SCHEMBL5793270 | 0.86 | DRD2 (0.46) | DRD2NAMPTEPHX2MEN1KMT2A | |
| SCHEMBL4232161 | 0.82 | NFKB1 (0.36) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL15765023 | 0.78 | MEN1 (0.38) | DRD2NAMPTMEN1KMT2ARORC | |
| SCHEMBL15765227 | 0.77 | NAMPT (0.38) | DRD2NAMPTEPHX2RORCACACB | |
| SCHEMBL15764957 | 0.77 | RORC (0.40) | DRD2NAMPTMEN1RAB9AKMT2A | |
| SCHEMBL5809553 | 0.77 | EZH2 (0.44) | DRD2NAMPTRORCACACBACACA | |
| SCHEMBL17987846 | 0.77 | RORC (0.41) | DRD2NAMPTRORC | |
| SCHEMBL4221927 | 0.76 | AQP1 (0.48) | DRD2 | |
| SCHEMBL8228747 | 0.75 | DRD2 (0.46) | DRD2NAMPTRORCACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938258-B2 | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | BCL6, MALT1, BCL3 | DRD2 2012/4885NAMPT 2985/4885EPHX2 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.